Stay updated with breaking news from Second Generation Product Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ZTALMY® Q3 net product revenue of $5.4 million; 2023 net product revenue guidance increased to between $18.5 and $19 million Over 75% of patients required for the interim analysis are now...
ZTALMY® first quarter U.S. net product revenue of $3.3 million Now planning to conduct an interim analysis for the Phase 3 refractory status epilepticus trial in the second half of... | May 11, 2023
ZTALMY® U.S. net product revenue of $2.3 million for the fourth quarter of 2022 and $2.9 million for the fiscal year ended December 31, 2022Company expects ZTALMY U.S. net product revenues of between $15 million and $17 million for the fiscal year ending December 31, 2023Second generation oral formulation developmen...
ZTALMY® can now be prescribed by healthcare professionals in the U.S.Second generation ganaxolone formulation demonstrates encouraging results in Phase 1 study in healthy volunteers and supports further clinical developmentMarinus’ Phase 2 refractory status epilepticus (RSE) trial data published in Epilepsia in June...